View Future GrowthAion Therapeutic 過去の業績過去 基準チェック /06Aion Therapeuticの収益は年間平均-506%の割合で減少していますが、 Pharmaceuticals業界の収益は年間 増加しています。収益は年間10.7% 563.3%割合で 増加しています。主要情報-506.02%収益成長率-163.65%EPS成長率Pharmaceuticals 業界の成長5.95%収益成長率563.34%株主資本利益率n/aネット・マージン-451.18%前回の決算情報31 Jan 2025最近の業績更新更新なしすべての更新を表示Recent updatesお知らせ • Oct 23Aion Therapeutic Inc. Announces Resignation of Larry Horwitz as DirectorAion Therapeutic Inc. announcing that Larry Horwitz resigned as a director effective October 18, 2024. The Company's board of directors currently consists of four directors.お知らせ • Oct 22Aion Therapeutic Inc. announced that it has received CAD 0.5 million in fundingAion Therapeutic Inc. announces that it intends to complete a non-brokered private placement offering of 33,333,333 units at a price of CAD 0.015 per unit for gross proceeds of CAD 500,000 on October 21, 2024. Each Unit will consist of one common share and one half of one common share purchase warrant. Each full Warrant will be exercisable to acquire one Share for a period of eighteen months following the closing of the Offering, at an exercise price of $0.05 per Warrant Share. All securities issued in connection with the Offering will be subject to a four month and one day hold as required under applicable securities laws.お知らせ • Apr 23Aion Therapeutic Inc. announced that it expects to receive CAD 0.75 million in fundingAion Therapeutic Inc. announced a non-brokered private placement of up to 50,000,000 units at a price of CAD 0.015 per unit for total gross proceeds of up to CAD 750,000 on April 22, 2024. Each unit consists of one common share and one common share purchase warrant. Each warrant will be exercisable to acquire one share for a period of eighteen months following the closing of the offering, at an exercise price of CAD 0.05 per warrant share. All securities issued in connection with the offering will be subject to a four month and one day hold as required under applicable securities laws.お知らせ • Oct 24Toppen Health Inc. entered into a definitive share purchase agreement to acquire Aion Therapeutic Inc. (CNSX:AION) for CAD 6.7 million in a reverse merger transaction.Toppen Health Inc. entered into a definitive share purchase agreement to acquire Aion Therapeutic Inc. (CNSX:AION) for CAD 6.7 million in a reverse merger transaction on October 10, 2023. The Purchase Consideration shall be satisfied through the issuance of 200,000,000 common shares in the capital of AION, to be issued at a deemed price of CAD 0.05 per share. AION may also be required to pay contingent consideration of $2,000,000 (CAD 2.74 million) if Toppen achieves revenue equal to or greater than $5,000,000 (CAD 6.84 million) for the period from October 18, 2023 to April 30, 2025. The completion of the Proposed Acquisition is subject to the successful completion of the Company’s due diligence review of Toppen, the approval of the Canadian Securities Exchange and other customary closing conditions. The completion of the Proposed Acquisition is currently expected to occur by the end of 2023.お知らせ • Oct 06Aion Therapeutic Inc. announced that it has received CAD 0.6425 million in fundingOn October 5, 2023, Aion Therapeutic Inc. closed the transaction. The company has issued 21,500,000 units at a price of CAD 0.01 per unit, for gross proceeds of CAD 215,000 in its second tranche closing. Including the first tranche of the unit offering, the company has issued a total of 64,250,000 units for total gross proceeds of CAD 642,500 in the transaction.お知らせ • Aug 15Aion Therapeutic Inc. announced that it has received CAD 0.4275 million in fundingOn August 14, 2023, Aion Therapeutic Inc. closed the transaction. The company issued 42,750,000 units at an issue price of CAD 0.01 per unit for the gross proceeds of CAD 427,500. Each Unit consists of one common share and one half of one common share purchase warrant. Each full Warrant is exercisable to acquire one Share for a period of eighteen months following the closing of the Unit Offering at an exercise price of CAD 0.10 per Warrant Share. All securities issued in connection with the Unit Offering are subject to a four month and one day hold as required under applicable securities laws.お知らせ • Jul 07Aion Therapeutic Announces Resignation of Rosy Mondin as DirectorAion Therapeutic Inc. announced that effective July 5, 2023, Rosy Mondin has resigned as a director of the Company.お知らせ • Jul 06Aion Therapeutic Inc. announced that it expects to receive CAD 0.5 million in fundingAion Therapeutic Inc announced a non-brokered private placement of up to 50,000,000 units at a price of CAD 0.01 per share for gross proceeds of up to CAD 500,000 on July 4, 2023. Each unit consisting of one common share and one-half of one common share purchase warrant. Each full warrant will be exercisable to acquire one share for a period of 18 months following the closing of the unit offering at an exercise price of CAD 0.1 per warrant share. The transaction is expected to close on or about July 31, 2023.収支内訳Aion Therapeutic の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史OTCPK:ANTC.F 収益、費用、利益 ( )CAD Millions日付収益収益G+A経費研究開発費31 Jan 251-72031 Oct 241-72031 Jul 241-62030 Apr 240-61031 Jan 240-11031 Oct 230-11031 Jul 230-11030 Apr 23001031 Jan 230-21031 Oct 220-21031 Jul 220-31130 Apr 220-41131 Jan 220-72131 Oct 210-82031 Jul 210-82030 Apr 210-82031 Jan 210-32031 Oct 200-21031 Jul 200-11030 Apr 200-11031 Jan 200-11031 Oct 190-11031 Jul 190-52030 Apr 190-51031 Jan 190-630質の高い収益: ANTC.Fは現在利益が出ていません。利益率の向上: ANTC.Fは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: ANTC.Fの過去 5 年間の前年比収益成長率がプラスであったかどうかを判断するにはデータが不十分です。成長の加速: ANTC.Fの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: ANTC.Fは利益が出ていないため、過去 1 年間の収益成長をPharmaceuticals業界 ( -6% ) と比較することは困難です。株主資本利益率高いROE: ANTC.Fの負債は資産を上回っているため、自己資本利益率を計算することは困難です。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/19 01:45終値2026/05/29 00:00収益2025/01/31年間収益2024/04/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Aion Therapeutic Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Oct 23Aion Therapeutic Inc. Announces Resignation of Larry Horwitz as DirectorAion Therapeutic Inc. announcing that Larry Horwitz resigned as a director effective October 18, 2024. The Company's board of directors currently consists of four directors.
お知らせ • Oct 22Aion Therapeutic Inc. announced that it has received CAD 0.5 million in fundingAion Therapeutic Inc. announces that it intends to complete a non-brokered private placement offering of 33,333,333 units at a price of CAD 0.015 per unit for gross proceeds of CAD 500,000 on October 21, 2024. Each Unit will consist of one common share and one half of one common share purchase warrant. Each full Warrant will be exercisable to acquire one Share for a period of eighteen months following the closing of the Offering, at an exercise price of $0.05 per Warrant Share. All securities issued in connection with the Offering will be subject to a four month and one day hold as required under applicable securities laws.
お知らせ • Apr 23Aion Therapeutic Inc. announced that it expects to receive CAD 0.75 million in fundingAion Therapeutic Inc. announced a non-brokered private placement of up to 50,000,000 units at a price of CAD 0.015 per unit for total gross proceeds of up to CAD 750,000 on April 22, 2024. Each unit consists of one common share and one common share purchase warrant. Each warrant will be exercisable to acquire one share for a period of eighteen months following the closing of the offering, at an exercise price of CAD 0.05 per warrant share. All securities issued in connection with the offering will be subject to a four month and one day hold as required under applicable securities laws.
お知らせ • Oct 24Toppen Health Inc. entered into a definitive share purchase agreement to acquire Aion Therapeutic Inc. (CNSX:AION) for CAD 6.7 million in a reverse merger transaction.Toppen Health Inc. entered into a definitive share purchase agreement to acquire Aion Therapeutic Inc. (CNSX:AION) for CAD 6.7 million in a reverse merger transaction on October 10, 2023. The Purchase Consideration shall be satisfied through the issuance of 200,000,000 common shares in the capital of AION, to be issued at a deemed price of CAD 0.05 per share. AION may also be required to pay contingent consideration of $2,000,000 (CAD 2.74 million) if Toppen achieves revenue equal to or greater than $5,000,000 (CAD 6.84 million) for the period from October 18, 2023 to April 30, 2025. The completion of the Proposed Acquisition is subject to the successful completion of the Company’s due diligence review of Toppen, the approval of the Canadian Securities Exchange and other customary closing conditions. The completion of the Proposed Acquisition is currently expected to occur by the end of 2023.
お知らせ • Oct 06Aion Therapeutic Inc. announced that it has received CAD 0.6425 million in fundingOn October 5, 2023, Aion Therapeutic Inc. closed the transaction. The company has issued 21,500,000 units at a price of CAD 0.01 per unit, for gross proceeds of CAD 215,000 in its second tranche closing. Including the first tranche of the unit offering, the company has issued a total of 64,250,000 units for total gross proceeds of CAD 642,500 in the transaction.
お知らせ • Aug 15Aion Therapeutic Inc. announced that it has received CAD 0.4275 million in fundingOn August 14, 2023, Aion Therapeutic Inc. closed the transaction. The company issued 42,750,000 units at an issue price of CAD 0.01 per unit for the gross proceeds of CAD 427,500. Each Unit consists of one common share and one half of one common share purchase warrant. Each full Warrant is exercisable to acquire one Share for a period of eighteen months following the closing of the Unit Offering at an exercise price of CAD 0.10 per Warrant Share. All securities issued in connection with the Unit Offering are subject to a four month and one day hold as required under applicable securities laws.
お知らせ • Jul 07Aion Therapeutic Announces Resignation of Rosy Mondin as DirectorAion Therapeutic Inc. announced that effective July 5, 2023, Rosy Mondin has resigned as a director of the Company.
お知らせ • Jul 06Aion Therapeutic Inc. announced that it expects to receive CAD 0.5 million in fundingAion Therapeutic Inc announced a non-brokered private placement of up to 50,000,000 units at a price of CAD 0.01 per share for gross proceeds of up to CAD 500,000 on July 4, 2023. Each unit consisting of one common share and one-half of one common share purchase warrant. Each full warrant will be exercisable to acquire one share for a period of 18 months following the closing of the unit offering at an exercise price of CAD 0.1 per warrant share. The transaction is expected to close on or about July 31, 2023.